Ponesimod Compared With Teriflunomide in Patients With Relapsing Multiple Sclerosis in the Active-Comparator Phase 3 OPTIMUM Study: A Randomized Clinical Trial

IMPORTANCE: To our knowledge, the Oral Ponesimod Versus Teriflunomide In Relapsing Multiple Sclerosis (OPTIMUM) trial is the first phase 3 study comparing 2 oral disease-modifying therapies for relapsing multiple sclerosis (RMS). OBJECTIVE: To compare the efficacy of ponesimod, a selective sphingosi...

Descripción completa

Detalles Bibliográficos
Autores principales: Kappos, Ludwig, Fox, Robert J., Burcklen, Michel, Freedman, Mark S., Havrdová, Eva K., Hennessy, Brian, Hohlfeld, Reinhard, Lublin, Fred, Montalban, Xavier, Pozzilli, Carlo, Scherz, Tatiana, D'Ambrosio, Daniele, Linscheid, Philippe, Vaclavkova, Andrea, Pirozek-Lawniczek, Magdalena, Kracker, Hilke, Sprenger, Till
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Medical Association 2021
Materias:
Original Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8008435/
https://www.ncbi.nlm.nih.gov/pubmed/33779698
http://dx.doi.org/10.1001/jamaneurol.2021.0405

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8008435/
https://www.ncbi.nlm.nih.gov/pubmed/33779698
http://dx.doi.org/10.1001/jamaneurol.2021.0405

Ejemplares similares